• Ultherapy® is celebrating 1 million treatments worldwide

    Since it's market entry in 2008, Ultherapy® has grown into a global leader among nonsurgical aesthetic and medical applications. It just reached a monumental milestone - one million treatments worldwide. It's time to celebrate.

    Learn more about the nonsurgicallift that's making beautiful changes arround the world.

    Read more

  • Dedicated to the development of botulinum neurotoxin for therapeutic use

    For patients with movement disorders, botulinum neurotoxin is often the treatment of choice. Merz´s expertise in this area has produced the only botulinum neurotoxin free from complexing proteins.

    Read more

    We are constantly working to advance new treatment standards and improve the quality of research, education and patient care.

    Read more

  • What do people really need?

    That was the key question of Friedrich Merz.

    The mindset of company founder Friedrich Merz continues to guide Merz today. In everything we do, our goal is to make a significant contribution to human well-being.

    Read more

    Merz has set itself an ambitious vision for the coming years focusing on two pillars: Aesthetics and Neurotoxins.

    Read more

  • Foster growth and create value

    Merz offers funding in early stage projects from emerging companies or academic institutions. In addition to our financial investment, we also offer provision of expertise.

    Read more

    As a leading international Aesthetics company we plan to invest globally in aesthetic healthcare companies pursuing innovative, breakthrough science.

    Read more

ONE MILLION LIFTS -
one beautiful world

Latest News

Merz Celebrates a Monumental Milestone: One Million Treatments Worldwide with Ultherapy®

Frankfurt /

Merz Aesthetics, a division of Merz Pharma Group, announced today that Ultherapy® is celebrating the milestone achievement of conducting one million treatments globally. Since its global launch in 2008 and…

Read more

Merz Appoints Bob Rhatigan as President and Chief Executive Officer in North AmericaPatrick Urban also named Chief Commercial Officer

Frankfurt am Main, Germany and Raleigh, NC, USA /

Merz Pharma, a global leader in aesthetics and neurotoxins, today announced the appointment of Bob Rhatigan as President and Chief Executive Officer (CEO) of Merz North America and Patrick Urban…

Read more

Merz Invests 15 Million Euros in New Production Plant for Dermal Fillers

Frankfurt am Main, Germany /

Merz Pharma is constructing a new production plant costing EUR 15 million to produce dermal fillers at its site in Dessau. The building, covering an area of approximately 1,200 square meters, is due…

Read more

E-Mail


Please leave this field empty.

* mandatory fields

Please note that if you submit information to Merz all materials submitted by electronic or physical communication will be deemed non-confidential. Do not submit any information or other materials that you consider to be confidential or proprietary. While we have no intention to publicly disclose any details of your proposal, we may refer to select experts within or outside the Merz network for evaluation.